Results 21 to 30 of about 359,465 (284)
Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease [PDF]
Objective To determine whether sulfonylurea use, compared with non-sulfonylurea oral diabetes medication use, was associated with 2-year mortality in individuals with well-controlled diabetes and coronary artery disease (CAD). Research design and methods
Berkowitz, Seth A +7 more
core +3 more sources
Testing proportional hazards for specified covariates
Tests for proportional hazards assumption concerning specified covariates or groups of covariates are proposed. The class of alternatives is wide: log-hazard rates under different values of covariates may cross, approach, go away.
Vilijandas Bagdonavičius +1 more
doaj +1 more source
Analysis of time to event outcomes in randomized controlled trials by generalized additive models. [PDF]
BACKGROUND:Randomized Controlled Trials almost invariably utilize the hazard ratio calculated with a Cox proportional hazard model as a treatment efficacy measure.
Christos Argyropoulos, Mark L Unruh
doaj +1 more source
Background Most clinical trials with time-to-event primary outcomes are designed assuming constant event rates and proportional hazards over time. Non-constant event rates and non-proportional hazards are seen increasingly frequently in trials.
Kim Jachno +2 more
doaj +1 more source
Time and dose dependency of bone-sarcomas in patients injected with radium-224 [PDF]
The time course and dose dependency of the incidence of bone-sarcomas among 900 German patients treated with high doses of radium-224 is analysed in terms of a proportional hazards model with a log-normal dependency of time to tumor and a linear ...
A. M. Kellerer +14 more
core +1 more source
Weighted Cox Regression Using the R Package coxphw
Cox's regression model for the analysis of survival data relies on the proportional hazards assumption. However, this assumption is often violated in practice and as a consequence the average relative risk may be under- or overestimated.
Daniela Dunkler +3 more
doaj +1 more source
Treating non-responders: pitfalls and implications for cancer immunotherapy trial design
Background Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment.
Zhenzhen Xu +3 more
doaj +1 more source
A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching [PDF]
In confirmatory cancer clinical trials, overall survival (OS) is normally a primary endpoint in the intention-to-treat (ITT) analysis under regulatory standards. After the tumor progresses, it is common that patients allocated to the control group switch
Bore, Alexander +3 more
core +2 more sources
Which test for crossing survival curves? A user’s guideline
Background The exchange of knowledge between statisticians developing new methodology and clinicians, reviewers or authors applying them is fundamental. This is specifically true for clinical trials with time-to-event endpoints.
Ina Dormuth +5 more
doaj +1 more source
Partially linear censored quantile regression [PDF]
Censored regression quantile (CRQ) methods provide a powerful and flexible approach to the analysis of censored survival data when standard linear models are felt to be appropriate.
B Honore +17 more
core +1 more source

